The ICR responds to the FDA approval of olaparib for women with BRCA-mutant​​ advanced breast cancer

The Institute of Cancer Research, London, strongly welcomes the news that olaparib has been approved by the US Food and Drug Administration (FDA) for patients with advanced breast cancer.
Institute of Cancer Research